Gene Editing Precision and Efficiency Soar! EDITGENE Launches Upgraded Gene Point Mutation Technology: Prime Editing 7

Prime Editing (PE) is an advanced gene-editing technology based on the CRISPR/Cas system, enabling precise insertions, deletions, and base substitutions at specific genomic sites. By integrating Cas proteins, reverse transcriptase, and specially designed guide RNAs (prime editing guide RNAs, or pegRNAs), PE surpasses the limitations of traditional mutation techniques, offering both high precision and broad versatility.

EDITGENE has recently achieved a major breakthrough with its Prime Editing technology, officially launching PE7! Whether in foundational research or at the frontier of advanced applications, PE7 redefines what’s possible in gene editing. With stronger editing capabilities, improved efficiency, and broader applicability, PE7 is the ultimate tool for researchers aiming for precision in gene editing!

Prime Editing 7 Technology Highlights

1、20% Higher Success Rate – Achieve Results with Confidence!

Thanks to EDITGENE’s advancements, PE7 has optimized the binding activity between editing proteins and RNA, boosting point mutation success rates by 20% compared to PE5. This isn’t just a number—each experiment is now more precise and reliable. Higher success rates mean less stress and lower costs, allowing researchers to focus on groundbreaking discoveries.

2、4.7x Increased Efficiency at Challenging Sites – Turning Challenges into Opportunities!

PE7 brings a major performance boost, reaching up to 86% editing efficiency at easy-to-edit sites (where PE5’s efficiency was above 20%). The real strength of PE7 is its power to tackle tough sites: for challenging targets where PE5’s efficiency was under 20%, PE7 raises efficiency by 1.76x to 4.71x! With PE7, previously difficult editing tasks become achievable, opening doors to new research possibilities.

The fold increase in editing efficiency of PE7 compared to PE5

Sites where editing failed via PE5, but were successfully edited via PE7

Note: 1 grade<10%, 2 grade20%-30%, 3 grade30%-40%,4 grade50%-60%,5 grade 70%-100%

Improvement in editing efficiency of PE7 compared to PE5

Note: 1 grade<10%, 2 grade20%-30%, 3 grade30%-40%,4 grade50%-60%,5 grade 70%-100%

Why Choose EDITGENE's PE7? Its unmatched performance will transform your research progress.

EDITGENE isn't just upgrading technology—it's transforming gene editing. Whether you're studying gene functions, developing new drugs, or advancing precision medicine, PE7 is the ultimate tool for your research. Imagine the time-consuming, complex gene editing tasks of the past, now made easy with PE7. Each attempt at gene editing becomes a crucial step toward groundbreaking discoveries.

Experience the limitless possibilities of gene editing with EDITGENE's Prime Editing 7. Take control of your next research breakthrough!

EDITGENE is an innovative company founded by PhD scholars with international experience, specializing in the research, development, and commercialization of CRISPR/Cas gene editing technology. Leveraging CRISPR/Cas technology, EDITGENE has developed foundational research platforms, including CRISPR-EDITx™ platform, the Bingo™ leading-edge point mutation platform and the FASST nucleic acid diagnostic platform.EDITGENE has provided comprehensive CRO services to research institutes and pharmaceutical companies worldwide, covering applications such as gene knockout、gene overexpression、point mutation and CRISPR library screening，Additionally, EDITGENE offers CRISPR detection enzymes (such as cas12 and cas13) and custom development services.In the coming future, EDITGENE plans to build the largest and most comprehensive gene editing service platform, providing a full range of gene editing-related services. With the mission of facilitating the widespread application of CRISPR/Cas technology, EDITGENE is committed to advancing the gene editing revolution and driving progress in the science field.